Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Current Assets (2016 - 2025)

Historic Current Assets for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to $61.8 million.

  • Cardiff Oncology's Current Assets rose 416.13% to $61.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.8 million, marking a year-over-year increase of 416.13%. This contributed to the annual value of $95.1 million for FY2024, which is 2278.97% up from last year.
  • Per Cardiff Oncology's latest filing, its Current Assets stood at $61.8 million for Q3 2025, which was up 416.13% from $73.7 million recorded in Q2 2025.
  • Cardiff Oncology's 5-year Current Assets high stood at $146.1 million for Q4 2021, and its period low was $59.3 million during Q3 2024.
  • Its 5-year average for Current Assets is $100.5 million, with a median of $95.1 million in 2024.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 115032.72% in 2021, then plummeted by 3287.47% in 2024.
  • Quarter analysis of 5 years shows Cardiff Oncology's Current Assets stood at $146.1 million in 2021, then dropped by 23.84% to $111.3 million in 2022, then plummeted by 30.44% to $77.4 million in 2023, then increased by 22.79% to $95.1 million in 2024, then tumbled by 34.98% to $61.8 million in 2025.
  • Its last three reported values are $61.8 million in Q3 2025, $73.7 million for Q2 2025, and $82.7 million during Q1 2025.